| Year |
Citation |
Score |
| 2022 |
Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Mukherjee SD, Mackey JR, et al. Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. Jama. 327: 1963-1973. PMID 35608580 DOI: 10.1001/jama.2022.6147 |
0.302 |
|
| 2022 |
Friedenreich CM, Vallance JK, McNeely ML, Culos-Reed SN, Matthews CE, Bell GJ, Mackey JR, Kopciuk KA, Dickau L, Wang Q, Cook D, Wharton S, McNeil J, Ryder-Burbidge C, Morielli AR, et al. The Alberta moving beyond breast cancer (AMBER) cohort study: baseline description of the full cohort. Cancer Causes & Control : Ccc. 33: 441-453. PMID 35064432 DOI: 10.1007/s10552-021-01539-6 |
0.308 |
|
| 2021 |
An KY, Arthuso FZ, Kang DW, Morielli AR, Ntoukas SM, Friedenreich CM, McKenzie DC, Gelmon K, Mackey JR, Courneya KS. Exercise and health-related fitness predictors of chemotherapy completion in breast cancer patients: pooled analysis of two multicenter trials. Breast Cancer Research and Treatment. PMID 33779887 DOI: 10.1007/s10549-021-06205-8 |
0.32 |
|
| 2020 |
Maayah ZH, Takahara S, Alam AS, Ferdaoussi M, Sutendra G, El-Kadi AOS, Mackey JR, Pituskin E, Paterson DI, Dyck JRB. Breast cancer diagnosis is associated with relative left ventricular hypertrophy and elevated endothelin-1 signaling. Bmc Cancer. 20: 751. PMID 32787791 DOI: 10.1186/s12885-020-07217-1 |
0.327 |
|
| 2018 |
Press MF, Seoane JA, Curtis C, Quinaux E, Guzman R, Sauter G, Eiermann W, Mackey JR, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Bee V, Ma Y, et al. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines. Jama Oncology. PMID 30520947 DOI: 10.1001/Jamaoncol.2018.6012 |
0.313 |
|
| 2016 |
Courneya KS, McNeely ML, Culos-Reed SN, Vallance JK, Bell GJ, Mackey JR, Matthews CE, Morielli AR, Cook D, MacLaughlin S, Farris MS, Voaklander S, O'Reilly R, Friedenreich CM. The Alberta Moving Beyond Breast Cancer (AMBER) Cohort Study: Recruitment, Baseline Assessment, and Description of the First 500 Participants. Bmc Cancer. 16: 481. PMID 27416835 DOI: 10.1186/s12885-016-2534-4 |
0.301 |
|
| 2016 |
Bekele RT, Venkatraman G, Liu RZ, Tang X, Mi S, Benesch MG, Mackey JR, Godbout R, Curtis JM, McMullen TP, Brindley DN. Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance. Scientific Reports. 6: 21164. PMID 26883574 DOI: 10.1038/Srep21164 |
0.302 |
|
| 2015 |
Mackey JR, Ramos-Vazquez M, Lipatov O, McCarthy N, Krasnozhon D, Semiglazov V, Manikhas A, Gelmon KA, Konecny GE, Webster M, Hegg R, Verma S, Gorbunova V, Abi Gerges D, Thireau F, et al. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 141-8. PMID 25185099 DOI: 10.1200/JCO.2014.57.1513 |
0.301 |
|
| 2013 |
Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. The Lancet. Oncology. 14: 933-42. PMID 23932548 DOI: 10.1016/S1470-2045(13)70335-8 |
0.321 |
|
| 2012 |
Dechaphunkul A, Phukaoloun M, Kanjanapradit K, Graham K, Ghosh S, Santos C, Mackey JR. Prognostic significance of tissue inhibitor of metalloproteinase-1 in breast cancer. International Journal of Breast Cancer. 2012: 290854. PMID 22988515 DOI: 10.1155/2012/290854 |
0.309 |
|
| 2012 |
Liu RZ, Graham K, Glubrecht DD, Lai R, Mackey JR, Godbout R. A fatty acid-binding protein 7/RXRβ pathway enhances survival and proliferation in triple-negative breast cancer. The Journal of Pathology. 228: 310-21. PMID 22322885 DOI: 10.1002/Path.4001 |
0.302 |
|
| 2010 |
Dumontet C, Krajewska M, Treilleux I, Mackey JR, Martin M, Rupin M, Lafanechère L, Reed JC. BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3988-97. PMID 20576719 DOI: 10.1158/1078-0432.CCR-10-0079 |
0.323 |
|
| 2009 |
Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, Magherini E, Mackey J, Martin M, Vogel C. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1168-76. PMID 19204205 DOI: 10.1200/Jco.2008.18.1024 |
0.303 |
|
| 2008 |
Piccart-Gebhart MJ, Burzykowski T, Buyse M, Sledge G, Carmichael J, Lück HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1980-6. PMID 18421049 DOI: 10.1200/JCO.2007.10.8399 |
0.301 |
|
| 2008 |
Courneya KS, McKenzie DC, Reid RD, Mackey JR, Gelmon K, Friedenreich CM, Ladha AB, Proulx C, Lane K, Vallance JK, Segal RJ. Barriers to supervised exercise training in a randomized controlled trial of breast cancer patients receiving chemotherapy. Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine. 35: 116-22. PMID 18347912 DOI: 10.1007/s12160-007-9009-4 |
0.308 |
|
| 2007 |
Verma S, Wong NS, Trudeau M, Joy A, Mackey J, Dranitsaris G, Clemons M. Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane. American Journal of Clinical Oncology. 30: 297-302. PMID 17551309 DOI: 10.1097/01.coc.0000258125.97090.3f |
0.314 |
|
| 2005 |
Verma S, Trudeau M, Dranitsaris G, Clemons M, Joy AA, MacKey JR. What is the best chemotherapy treatment option for anthracycline and taxane pretreated metastatic breast cancer? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6260; author reply 6. PMID 16135495 DOI: 10.1200/JCO.2004.00.9886 |
0.305 |
|
| 2002 |
Mackey JR, Jennings LL, Clarke ML, Santos CL, Dabbagh L, Vsianska M, Koski SL, Coupland RW, Baldwin SA, Young JD, Cass CE. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 110-6. PMID 11801546 |
0.305 |
|
| Show low-probability matches. |